Downgrades Overweight Neutral X

TMDX TransMedics Group

JP Morgan

$116 $75

Downgrades Buy Hold X

TMDX TransMedics Group

Needham

Reiterated Buy X

TMDX TransMedics Group

Needham

$208 $109

Reiterated Outperform X

TMDX TransMedics Group

Oppenheimer

$200 $125

Initiated Outperform X

TMDX TransMedics Group

Robert W. Baird

$200

Initiated Buy X

TMDX TransMedics Group

Needham

$208

Initiated Overweight X

TMDX TransMedics Group

Stephens

$151

Initiated Overweight X

TMDX TransMedics Group

Piper Sandler

$95

Initiated Outperform X

TMDX TransMedics Group

Robert W. Baird

Upgrades Neutral Overweight X

TMDX TransMedics Group

JP Morgan

$48

Initiated Buy X

TMDX TransMedics Group

Canaccord Genuity

Initiated Outperform X

TMDX TransMedics Group

Cowen

Initiated Overweight X

TMDX TransMedics Group

JP Morgan

Initiated Equal-Weight X

TMDX TransMedics Group

Morgan Stanley

TMDX  Transmedics Group, Inc.

Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. The company offers its products in the United States and internationally. Transmedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.